- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Moderate to severe hidradenitis suppurativa.
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 793KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 54KB)
Adalimumab – July 2021
Adalimumab: Injection 20 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL pre-filled pen; Abrilada®
Last updated
29 October 2021